Radiopharmaceuticals are used in nuclear medicine for diagnostic or therapeutic acts. The short decay half-lives of medical radioisotopes, especially those used for diagnostics, imply that they should be produced continuously and transported as quickly as possible to the medical units where they are used. Neutron-rich medical radioisotopes are generally produced in research reactors, like technetium-99m, lutetium-177, holmium-166 and iodine-131. On the other hand, proton-rich radioisotopes are produced via reactions with charged particles from accelerators like fluorine-18, gallium-67, iodine-123 and thallium-201. Beside this, innovative nuclear reactors are advocated as solutions to the issues of nuclear waste production and proliferation threats. Fast neutron, thorium-cycle and accelerator-driven subcritical (ADS) reactors are some of the most promising of them, proposed as safer fuel breeders and “waste burners”. This article examines the use of a fast thorium-cycle ADS with liquid lead-bismuth eutectic coolant for the production of molybdenum-99/technetium-99m and lutetium-177. Burnup simulation has been made with the Monte-Carlo (MC) code SERPENT. It is demonstrated that MC codes can advantageously be used to determine the optimal irradiation time for a given radioisotope in a realistic reactor core. It is also shown that fast thorium-cycle ADS is an economical option for the production of medical radioisotopes.
References
[1]
Oliver, C. (2017) Compact and Efficient Accelerators for Radioisotope Production. Proceedings of IPAC 2017, Copenhagen, 14-19 May 2017, 4824-4829.
https://accelconf.web.cern.ch/ipac2017/papers/frxba1.pdf
[2]
POSTNOTE (2017) Supply of Medical Radioisotopes. Parliamentary Office of Science & Technology, 558.
https://post.parliament.uk/research-briefings/post-pn-0558
[3]
OECD/NEA (2014) The Supply of Medical Radioisotopes: An Economic Diagnosis and Possible Solutions. OECD Publishing, Paris.
[4]
IAEA (2006) Annex VI: Advances in Medical Radiation Imaging for Cancer Diagnosis and Treatment. Nuclear Technology Review.
https://inis.iaea.org/search/search.aspx?orig_q=RN:37112943
[5]
O’Donnell, R.T. (2006) Nuclear Localizing Sequences: An Innovative Way to Improve Targeted Radiotherapy. Journal of Nuclear Medicine, 47, 738-739.
[6]
Owen, H.L., Ballinger, J., Buscombe, J., Clarke, R., Denton, E., Ellis, B., Flux, G., Fraser, L., Neilly, B., Paterson, A., Perkins, A.C. and Scarsbrook, A. (2014) Options for UK Technetium-99m Production Using Accelerators. Proceedings of the 5th International Particle Accelerator Conference, Dresden, 16-20 June 2014, 2815-1818.
http://cds.cern.ch/record/2158442
[7]
Dash, A., Pillai, M.R.A. and Knapp Jr., F.F. (2015) Production of 177Lu for Targeted Radionuclide Therapy: Available Options. Nuclear Medicine and Molecular Imaging, 49, 85-107. https://doi.org/10.1007/s13139-014-0315-z
[8]
Dash, A., Pillai, M.R.A. and Knapp, F.F. (2015) Production of 177Lu for Targeted Radionuclide Therapy: Available Options. Nuclear Medicine Molecular Imaging, 49, 85-107. https://doi.org/10.1007/s13139-014-0315-z
[9]
Sahin, H. and Abderrahim, H.A. (2012) Multi-Purpose Hybrid Research Reactor for High-Tech Applications. International Journal of Energy Research, 36, 1331-1337.
https://doi.org/10.1002/er.1891
[10]
Bakir, G., Selçuklu, S.B. and Yapici, H. (2016) Medical Radioisotope Production in a Power-Flattened ADS Fuelled with Uranium and Plutonium Dioxides. Science and Technology of Nuclear Installations, 2016, Article ID: 5302176.
https://doi.org/10.1155/2016/5302176
[11]
Carminati, F., Klapisch, R., Revol, J.P., Roche, C., Rubio, J.A. and Rubbia, C. (1993) An Energy Amplifier for Cleaner and Inexhaustible Nuclear Energy Production Driven by a Particle Beam Accelerator. CERN-AT-93-47-ET.
https://cds.cern.ch/record/256520/files/at-93-047.pdf
[12]
Mushtaq, A. (2012) Producing Radioisotopes in Power Reactors. Journal of Radioanalytical Nuclear Chemistry, 292, 793-802.
https://doi.org/10.1007/s10967-011-1537-5
[13]
Graiciany de Paula Barros, G.P., Pereira, C., Veloso, M.A.F. and Costa, A.L. (2012) Study of an ADS Loaded with Thorium and Reprocessed Fuel. Science and Technology of Nuclear Installations, 2012, Article ID: 934105.
https://doi.org/10.1155/2012/934105
[14]
Pazirandeh, A. and Shirmohammadi, L. (2015) Simulation of an Accelerator Driven Subcritical Core with Mixed Uranium-Thorium Fuel. World Journal of Engineering and Technology, 3, 328-333. https://doi.org/10.4236/wjet.2015.33C049
[15]
Gulik, V. and Tkaczyk, A.H. (2013) Optimization of Geometry, Material and Economic Parameters of a Two-Zone Subcritical Reactor for Transmutation of Nuclear Waste with SERPENT Monte Carlo Code. Proceedings of the Joint International Conference on Supercomputing in Nuclear Applications and Monte Carlo 2013, Paris, 14-21 October 2013, 01102. https://doi.org/10.1051/snamc/201401102
[16]
Ballarini, F., Battistoni, G., Cerutti, F., Empl, A., Fassò, A., Ferrari, A., Gadioli, E., Garzelli, M.V., Ottolenghi, A., Pinsky, L.S., Ranft, J., Roesler, S., Sala, P.R. and Scannicchio, D. (2003) Nuclear Models in FLUKA: A Review. Proceedings of the 10th International Conference on Nuclear Reaction Mechanisms, Varenna, 9-13 June 2003. http://www0.mi.infn.it/~gadioli/proceedings/ferrari.ps
[17]
National Research Council (US) Committee on Medical Isotope Production without Highly Enriched Uranium (2009) Medical Isotope Production without Highly Enriched Uranium: (Chap. 6) Molybdenum-99/Technetium-99m Production Costs. National Academies Press. https://www.ncbi.nlm.nih.gov/books/NBK215132
